{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:35:58Z","timestamp":1793277358445,"version":"4.5.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n As amyloid-targeted therapies have become commercially available, the monitoring of cerebral amyloid angiopathy (CAA), which is an important risk factor for amyloid-related imaging abnormalities, has received increasing attention. However, comprehensive evidence on the association between Alzheimer disease (AD) plasma biomarkers and various CAA imaging markers is still lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the association of CAA imaging markers with downstream AD plasma biomarkers in relation to amyloid-\u03b2 (A\u03b2) uptake on positron emission tomography (PET) and whether their interplay is associated with cognitive changes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This registry-based cohort study in 25 hospitals across South Korea recruited participants aged 45 years or older who were registered between January 1, 2016, and December 31, 2023. Participants were categorized as having no cognitive impairment, mild cognitive impairment, or dementia of the Alzheimer type.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Cerebral amyloid angiopathy imaging markers assessed by magnetic resonance imaging, including cerebral microbleeds (CMBs), cortical superficial siderosis, white matter hyperintensities, lacunes, and enlarged perivascular spaces.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Plasma phosphorylated tau-217 (p-tau217) was measured using a commercial assay. Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were measured using a single-molecule assay on a single platform. All participants underwent amyloid PET imaging. Associations of CAA and vascular imaging markers with downstream AD plasma biomarkers were investigated using linear regression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 1708 participants were included (mean [SD] age, 71.2 [8.4] years; 1044 female [61.1%]). The mean (SD) follow-up period was 4.3 (3.1) years. Lobar CMB counts and the presence of CAA were associated with downstream AD plasma biomarkers, including p-tau217 (\u03b2 = 0.12 [95% CI, 0.05-0.18] and 0.29 [95% CI, 0.12-0.47], respectively), GFAP (\u03b2 = 0.07 [95% CI, 0.03-0.12] and 0.20 [95% CI, 0.09-0.31], respectively), and NfL (\u03b2 = 0.07 [95% CI, 0.03-0.11] and 0.16 [95% CI, 0.06-0.25], respectively) with and without the mediation of A\u03b2 uptake on PET (indirect effect: lobar CMBs\u2013p-tau217, 59.8% [\u03b2 = 0.07 (95% CI, 0.03-0.11)]; lobar CMBs-GFAP, 49.3% [\u03b2 = 0.04 (95% CI, 0.01-0.06)]; lobar CMBs-NfL, 20.9% [\u03b2 = 0.01 (95% CI, 0.01-0.03)]; CAA\u2013p-tau217, 50.9% [\u03b2 = 0.15 (95% CI, 0.06-0.24)]; CAA-GFAP, 39.2% [\u03b2 = 0.08 (95% CI, 0.03-0.13)]; CAA-NfL, 19.2% [\u03b2 = 0.03 (95% CI, 0.01-0.05)]). Amyloid-\u03b2 uptake fully mediated the associations between cortical superficial siderosis and downstream AD plasma markers. In contrast, hypertensive arteriosclerotic vascular imaging markers, including lacunes, deep CMBs, and enlarged perivascular spaces in basal ganglia, were associated with only NfL levels (\u03b2 = 0.07 [95% CI, 0.01-0.13], 0.20 [95% CI, 0.08-0.32], and 0.14 [95% CI, 0.06-0.23], respectively), regardless of A\u03b2 uptake on PET. Finally, there were interactive associations of lobar CMBs in conjunction with p-tau217 levels (\u03b2 = \u22120.56 [95% CI, \u22120.79 to \u22120.34]) and GFAP levels (\u03b2 = \u22120.44 [95% CI, \u22120.70 to \u22120.17]) with annual Mini-Mental State Examination changes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of participants with no cognitive impairment, mild cognitive impairment, or dementia of the Alzheimer type, a novel association was found among CAA imaging markers, downstream AD plasma biomarkers, and cognitive declines in relation to brain A\u03b2 burdens. The findings emphasize the importance of understanding the clinical effects of amyloid-related imaging abnormality\u2013like CAA imaging markers in light of upcoming amyloid-targeted therapies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.8842","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:30:36Z","timestamp":1746790236000},"page":"e258842","source":"Crossref","is-referenced-by-count":15,"title":["Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers"],"prefix":"10.1001","volume":"8","author":[{"given":"Sung Hoon","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis"},{"name":"Indiana Alzheimer Disease Research Center, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ju","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Alzheimer\u2019s Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeun","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom"},{"name":"UK Dementia Research Institute at UCL, London, United Kingdom"},{"name":"Hong Kong Center for Neurodegenerative Diseases, Hong Kong, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Paris Brain Institute, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne University, Paris, France"},{"name":"Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of University of Science and Technology of China, Hefei, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King\u2019s College London, London, United Kingdom"},{"name":"National Institute of Health Research Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, United Kingdom"},{"name":"Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihwan","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Soonchunhyang University Bucheon Hospital, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Alzheimer\u2019s Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk L.","family":"Na","sequence":"additional","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Pyo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Alzheimer\u2019s Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea"},{"name":"Department of Digital Health, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea"},{"name":"Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea"},{"name":"Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"4","key":"zoi250320r1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi250320r2","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"4","key":"zoi250320r3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/WAD.0000000000000084","article-title":"Cerebral amyloid angiopathy-related inflammation presenting with rapidly progressive dementia, responsive to IVIg.","volume":"29","author":"Cenina","year":"2015","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"zoi250320r4","doi-asserted-by":"publisher","first-page":"15984","DOI":"10.1038\/s41598-017-16298-1","article-title":"Distinctive clinical effects of haemorrhagic markers in cerebral amyloid angiopathy.","volume":"7","author":"Jang","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"zoi250320r5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations.","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"1","key":"zoi250320r6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation.","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"12","key":"zoi250320r7","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","article-title":"The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease.","volume":"19","author":"Blennow","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"5","key":"zoi250320r8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials.","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"issue":"1","key":"zoi250320r9","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease.","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"7691","key":"zoi250320r10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u00df biomarkers for Alzheimer\u2019s disease.","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"5","key":"zoi250320r11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"issue":"5","key":"zoi250320r12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology.","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"8","key":"zoi250320r13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"zoi250320r14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes.","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurol"},{"issue":"12","key":"zoi250320r15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi250320r16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease.","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"1","key":"zoi250320r17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment.","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"zoi250320r18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"3","key":"zoi250320r19","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","article-title":"Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures.","volume":"93","author":"Mielke","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"zoi250320r20","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14526","article-title":"Differential roles of Alzheimer\u2019s disease plasma biomarkers in stepwise biomarker-guided diagnostics.","volume":"21","author":"Jang","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"2","key":"zoi250320r21","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12576","article-title":"Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort.","volume":"16","author":"Chong","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"zoi250320r22","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12396","article-title":"Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease.","volume":"15","author":"Chong","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"zoi250320r23","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12291","article-title":"Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer\u2019s disease and vascular pathology.","volume":"14","author":"Shir","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"zoi250320r24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3233\/JAD-220158","article-title":"Association between plasma biomarkers of amyloid, tau, and neurodegeneration with cerebral microbleeds.","volume":"87","author":"McCarter","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"zoi250320r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer\u2019s disease.","author":"Chen","journal-title":"J Prev Alzheimer Dis"},{"issue":"4","key":"zoi250320r26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.12779\/dnd.2024.23.4.212","article-title":"Korea-Registries to Overcome and Accelerate Dementia Research (K-ROAD): a cohort for dementia research and ethnic-specific insights.","volume":"23","author":"Jang","year":"2024","journal-title":"Dement Neurocogn Disord"},{"issue":"20","key":"zoi250320r27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"17","key":"zoi250320r28","doi-asserted-by":"publisher","first-page":"e2201","DOI":"10.1212\/WNL.0000000000011833","article-title":"Amyloid positivity in the Alzheimer\/subcortical-vascular spectrum.","volume":"96","author":"Kang","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"zoi250320r29","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00259-019-04314-7","article-title":"Clinical significance of amyloid \u00df positivity in patients with probable cerebral amyloid angiopathy markers.","volume":"46","author":"Jang","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"zoi250320r30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(09)70013-4","article-title":"Cerebral microbleeds: a guide to detection and interpretation.","volume":"8","author":"Greenberg","year":"2009","journal-title":"Lancet Neurol"},{"issue":"21","key":"zoi250320r31","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/WNL.0b013e3181c34a7d","article-title":"The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds.","volume":"73","author":"Gregoire","year":"2009","journal-title":"Neurology"},{"issue":"7","key":"zoi250320r32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/WNL.0b013e3182a08f2c","article-title":"Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy.","volume":"81","author":"Charidimou","year":"2013","journal-title":"Neurology"},{"issue":"8","key":"zoi250320r33","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.","volume":"21","author":"Charidimou","year":"2022","journal-title":"Lancet Neurol"},{"issue":"4","key":"zoi250320r34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.06.002","article-title":"A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities.","volume":"23","author":"Noh","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"7","key":"zoi250320r35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1474-4422(23)00131-X","article-title":"Neuroimaging standards for research into small vessel disease-advances since 2013.","volume":"22","author":"Duering","year":"2023","journal-title":"Lancet Neurol"},{"issue":"3","key":"zoi250320r36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/STROKEAHA.109.564914","article-title":"Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease.","volume":"41","author":"Doubal","year":"2010","journal-title":"Stroke"},{"issue":"8","key":"zoi250320r37","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","article-title":"Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.","volume":"12","author":"Wardlaw","year":"2013","journal-title":"Lancet Neurol"},{"issue":"1","key":"zoi250320r38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"12","key":"zoi250320r39","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","article-title":"18F-florbetaben PET beta-amyloid binding expressed in centiloids.","volume":"44","author":"Rowe","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"zoi250320r40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","article-title":"Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods.","volume":"8","author":"Battle","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1","key":"zoi250320r41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14368","article-title":"Plasma Alzheimer\u2019s disease biomarker variability: amyloid-independent and amyloid-dependent factors.","volume":"21","author":"Lee","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi250320r42","doi-asserted-by":"publisher","first-page":"15298","DOI":"10.1038\/s41598-022-19696-2","article-title":"Association of late-life body mass index with the risk of Alzheimer disease: a 10-year nationwide population-based cohort study.","volume":"12","author":"Cho","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"zoi250320r43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1017\/S1041610214001744","article-title":"Association between body mass index and cortical thickness: among elderly cognitively normal men and women.","volume":"27","author":"Kim","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"zoi250320r44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.nicl.2017.05.002","article-title":"Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: a systematic critical update.","volume":"15","author":"Farid","year":"2017","journal-title":"Neuroimage Clin"},{"issue":"14","key":"zoi250320r45","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1212\/WNL.0000000000004539","article-title":"Amyloid-PET in sporadic cerebral amyloid angiopathy: a diagnostic accuracy meta-analysis.","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"zoi250320r46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography.","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurol"},{"issue":"12","key":"zoi250320r47","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","article-title":"Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A\u00df-PET and cognition.","volume":"92","author":"Rauchmann","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"zoi250320r48","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u00df but not tau pathology in Alzheimer\u2019s disease.","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"9","key":"zoi250320r49","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3174\/ajnr.A4351","article-title":"Cerebral microbleeds, CSF p-tau, and cognitive decline: significance of anatomic distribution.","volume":"36","author":"Chiang","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"zoi250320r50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3233\/JAD-161139","article-title":"18F-AV-1451 PET imaging in three patients with probable cerebral amyloid angiopathy.","volume":"57","author":"Kim","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"zoi250320r51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nicl.2016.11.008","article-title":"Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.","volume":"13","author":"Seo","year":"2016","journal-title":"Neuroimage Clin"},{"issue":"4","key":"zoi250320r52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00401-005-1074-9","article-title":"Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms.","volume":"110","author":"Attems","year":"2005","journal-title":"Acta Neuropathol"},{"issue":"6","key":"zoi250320r53","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1212\/WNL.46.6.1592","article-title":"Cerebral amyloid angiopathy in the brains of patients with Alzheimer\u2019s disease: the CERAD experience, part XV.","volume":"46","author":"Ellis","year":"1996","journal-title":"Neurology"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833775\/kang_2025_oi_250320_1746203857.20576.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:30:37Z","timestamp":1746790237000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8842","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}